Hospital

SHR-A1811 shows significant antitumor activity in early-stage HER2+ breast cancer, both alone and with pyrotinib, promising improved treatment outcomes.

Maternal type 1 diabetes may influence children's DNA, potentially reducing their risk of developing islet autoimmunity.

New findings suggest omitting radiation therapy in postmastectomy breast cancer treatment enhances survival, emphasizing the role of systemic therapies.

The FDA approves daratumumab and hyaluronidase for high-risk smoldering multiple myeloma, significantly improving patient outcomes and progression-free survival.

Leukogene's M2T-CD33 gains FDA orphan drug status, promising a novel immunotherapy approach for acute myeloid leukemia treatment.

The move continues the push towards most favored nation (MFN) status, lowering the prices of glucagon-like peptide-1 (GLP-1s) drugs for Medicare recipients.

Gedatolisib shows promise in enhancing progression-free survival for HR+/HER2– breast cancer patients resistant to standard therapies, as revealed in ESMO 2025.

Discover the importance of early screening for type 1 diabetes and how it can prevent life-threatening complications.

Oral semaglutide shows promise in enhancing glucose control and reducing cardiovascular risks.

CAR-T and BsAb therapies revolutionize multiple myeloma treatment but pose infection risks, necessitating vigilant monitoring and tailored prevention strategies.

Explore the rising prevalence of diabetes in the US, its various types, and the critical role pharmacists play in patient care.

Shara Bialo, MD, emphasizes the critical role of autoantibody screening in early T1D detection, enhancing patient outcomes during American Diabetes Month.

RSV infections in multiple myeloma patients delay treatment but do not increase mortality, highlighting the need for further research on infection management.

Richard Kovacs, MD, underscores the pharmacist’s role in educating patients about sodium reduction, monitoring blood pressure, and ensuring safe transitions to low-sodium oxybate therapy.

Explore the risks of synthetic 7-hydroxymitragynine (7-OH) products and why natural leaf kratom is a safe alternative.

Although the incidence of vascular assess-associated infections (VAIs) was low, the incidence caused by noncuffed catheters (NCC) was high.

Continuous glucose monitoring (CGM) significantly enhances the detection of cystic fibrosis-related diabetes, outperforming traditional methods.

Research reveals a notable risk of invasive fungal infections in multiple myeloma patients undergoing BCMA-targeted CAR T-cell therapy, highlighting the need for vigilant monitoring.

Long-term benzodiazepine use has been linked to lasting cognitive impairments, underscoring the vital role pharmacists play in supporting safe deprescribing strategies.

Rajinder Shiwach, MD, MRCPsych, outlines how pharmacists can strengthen retention, patient education, and access to rapid induction strategies for opioid use disorder treatment.

Environmental factors significantly influence the rising rates of type 2 diabetes in children.

Richard Kovacs, MD, explains how switching from high-sodium to low-sodium oxybate led to meaningful blood pressure reductions and lower cardiovascular risk in patients with narcolepsy.

Rajinder Shiwach, MD, MRCPsych, discusses how rapid induction with extended-release buprenorphine improves patient retention and maintains comparable efficacy and tolerability to standard induction methods.

COVID-19 mRNA vaccines enhance immune checkpoint inhibitor effectiveness in cancer therapy, significantly improving survival rates for patients with advanced tumors.

The FDA approves a simplified single-injection treatment for ulcerative colitis, enhancing patient experience with monthly dosing convenience.

Oncologists increasingly embrace cell and gene therapies, yet barriers like cost and perceptions of risk hinder broader adoption.

Expert shares notable findings presented at the 2025 IMS Annual Meeting.

The FDA updates sotatercept's label, enhancing treatment options for pulmonary arterial hypertension and reducing severe clinical events.